No title
Ovarian cancer is one of the most lethal gynecological-related cancers and has a high recurrence rate. Its heterogeneity and immunosuppressive landscape pose challenges when assessing treatment options. Novel immunotherapy strategies have potential to overcome its challenges with heterogeneity and immunosuppression but have not been successful yet. Utilizing the cGAS-STING pathway is promising for
